Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291019 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL4316792 | 0.83 | DGAT1 (0.38) | KDM4EDGAT1LMNATSHRKCNN4 | |
| SCHEMBL1555747 | 0.80 | DGAT1 (0.39) | KDM4EDGAT1LMNATSHRKCNN4 | |
| SCHEMBL8153132 | 0.79 | KDM4E (0.40) | KDM4EDGAT1CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1315491 | 0.78 | KDM4E (0.38) | KDM4EDGAT1LMNATSHRKCNN4 | |
| Hydrochloric Acid SCHEMBL21963711 | 0.78 | KDM4E (0.38) | KDM4EDGAT1LMNATSHRKCNN4 | |
| Hydrochloric Acid SCHEMBL16742421 | 0.78 | DGAT1 (0.43) | KDM4EDGAT1 | |
| SCHEMBL10407133 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL18824865 | 0.76 | KDM4E (0.37) | KDM4EDGAT1LMNA | |
| Hydrochloric Acid SCHEMBL6264005 | 0.76 | CYP4F2 (0.50) | KDM4ELMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.I. (IT) | 2025-08-14 | — | — | US | disclosed |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119504554-A | Indole compounds and indole dimer compounds and their use as STING agonists | 深圳湾实验室 | 2025-02-25 | — | — | CN | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114929681-B | Bicyclic CX3CR1 receptor agonists | 德州大学系统董事会 | 2024-05-14 | — | — | CN | disclosed |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2024-05-09 | — | — | US | disclosed |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| CN-112105604-B | Novel compounds exhibiting intestinal peptidase inhibitory activity | 株式会社LG化学 | 2024-01-09 | — | — | CN | disclosed |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| WO-2015077502-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140249119-A1 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-5698526-A | ANTICHOLESTEROL AGENT | PFIZER INC. (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0737203-A1 | STEROIDAL GLYCOSIDES | PFIZER INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018144-A1 | STEROIDAL GLYCOSIDES | PFIZER INC. (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | KDM4E 4831/4885DGAT1 3271/4885LMNA 3542/4885 |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | EGLN3, HIF1AN, EGLN2 | KDM4E 72/4885DGAT1 3584/4885LMNA 3749/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | KDM4E 1019/4885DGAT1 2771/4885LMNA 2517/4885 |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | KDM4E 4831/4885DGAT1 3271/4885LMNA 3542/4885 |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | KDM4E 4831/4885DGAT1 3271/4885LMNA 3542/4885 |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | KDM4E 4004/4885DGAT1 583/4885LMNA 3264/4885 |
| US-20140249119-A1 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | AKR1A1, AKR1C3, AKR1C1 | KDM4E 1423/4885DGAT1 3424/4885LMNA 951/4885 |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | KDM4E 4004/4885DGAT1 583/4885LMNA 3264/4885 |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | KDM4E 4831/4885DGAT1 3271/4885LMNA 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.